The European Commission has approved TEPKINLY (epcoritamab) combined with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma in adults. This marks the first bispecific antibody-based therapy authorized in Europe for second-line treatment of this cancer, providing a chemotherapy-free alternative. The approval is based on Phase 3 EPCORE FL-1 trial results showing significantly better progression-free survival and response rates compared to standard treatment. Around 74% of patients achieved complete remission with TEPKINLY plus R2, highlighting its potential to change treatment approaches for this incurable lymphoma.
Halper Sadeh LLC is investigating whether shareholders of Arcosa, Bio-Techne, Iridium Communications, and LCI Industries are receiving fair deals in their companies' recent sales. The law firm suspects insiders may gain financial benefits not availab...
Law Offices of Howard G. Smith has announced upcoming deadlines for investors to file lead plaintiff motions in class action lawsuits against BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. These lawsuits allege that the compani...
The global waterborne epoxy resins market, valued at $4.98 billion in 2024, is projected to grow at a CAGR of 6.03% to $8.51 billion by 2034. This growth is fueled by strict international regulations targeting volatile organic compound emissions and ...
NEWMEDIA.COM highlights that top ecommerce web design agencies prioritize conversion and scale over just appearance, addressing the nearly 70% cart abandonment rate largely caused by fixable user experience issues like slow pages and complicated chec...
The global generative AI in healthcare market, valued at $1.84 billion in 2024, is projected to grow at a 31.4% CAGR to reach $21.64 billion by 2034. Growth is fueled by solutions for medical imaging, diagnostics, drug discovery, and administrative a...
